Palisade Bio Q3 net loss widens to $14.6M; ASCENTRA-UC dosing underway, topline set for Q4 2027

PALISADE BIO, INC.

2026-Q3 EPS reported -$0.16 revenue$500,000

Net loss $14.6M ($0.07/share) vs $2.9M ($0.38/share) in Q3 2025; R&D rose to $10.6M from $1.4M and G&A to $5.1M from $1.5M on PALI-2108 Phase 2 costs.
Cash and equivalents of $113.6M at September 30, 2026; company says this funds operations through the ASCENTRA-UC (Q4 2027) and ASCENTRA-CD (Q1 2028) efficacy readouts.
First patient dosed in Phase 2b ASCENTRA-UC on October 27, 2026; 29 of 30 U.S. sites activated, ~115 sites planned globally, ~204 patients, 15 mg and 30 mg vs placebo.
FDA cleared the Crohn's disease IND on September 22, 2026; Phase 2a ASCENTRA-CD (~60 patients, 30 mg once daily) enrollment targeted Q1 2027, primary readout Q1 2028.
Presented five posters at ACG 2026 and one oral plus three moderated posters at UEG Week 2026, including endoscopic improvement within two weeks in five fibrostenotic Crohn's patients.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.